[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100557946":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":18,"centralContacts":19,"locations":25,"responsibleParty":43,"collaborators":18,"id":45,"slug":46,"hasResults":47,"nctId":48,"briefTitle":49,"officialTitle":50,"acronym":18,"eligibilityCriteria":51,"healthyVolunteers":47,"sex":52,"minAge":53,"maxAge":18,"enrollmentInfo":54,"targetDuration":18,"studyType":57,"phases":58,"briefSummary":60,"conditions":61,"keywords":18,"overallStatus":28,"whyStopped":18,"lastUpdateSubmitDate":70,"lastUpdatePostDateStruct":71,"startDateStruct":74,"completionDateStruct":76,"leadSponsor":78,"locationsCount":79},{"fullName":5,"class":6},"The Affiliated Hospital of Qingdao University","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"SCG142 TCR-T cells","EXPERIMENTAL","Monotherapy of SCG142",[13],"Biological: SCG142 TCR-T cells",[15],{"type":16,"name":9,"description":11,"armGroupLabels":17,"otherNames":18},"BIOLOGICAL",[9],null,[20],{"name":21,"role":22,"phone":23,"phoneExt":18,"email":24},"Hongying Lv","CONTACT","+86 18661805217","qdlhytiger@163.com",[26],{"facility":27,"status":28,"city":29,"state":30,"zip":31,"country":32,"countryCode":33,"cosmosGeoPoint":34,"geoPoint":39,"contacts":40},"The affiliated hosptial of qingdao university","RECRUITING","Qingdao","Shandong","266071","China","CN",{"type":35,"coordinates":36},"Point",[37,38],120.38042,36.06488,{"lat":38,"lon":37},[41],{"name":21,"role":22,"phone":42,"phoneExt":18,"email":24},"18661805217",{"type":44,"investigatorFullName":18,"investigatorTitle":18,"investigatorAffiliation":18,"oldNameTitle":18,"oldOrganization":18},"SPONSOR","100557946","phase-1-scg142-tcr-t-cells-for-human-papillomavirus-associated-carcinomas-100557946",false,"NCT06544720","SCG142 TCR-T Cells for Human Papillomavirus-Associated Carcinomas","A Phase 1 Clinical Study of Autologous TCR-T Cells (SCG142) Therapy for Advanced HPV Associated Carcinomas","Key Inclusion Criteria:\n\n1. Greater than or equal to 18 years of age\n2. HPV associated carcinomas\n3. Patients must have at least one measurable lesion defined by RECIST 1.1\n4. Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1\n\nKey Exclusion Criteria:\n\n1. Active or uncontrollable infections or other active major medical illnesses of the cardiovascular, respiratory.\n2. Patients with active autoimmune diseases.\n3. Patient has a known active Hepatitis B or Hepatitis C.\n4. Other severe medical conditions that may limit subject\\'s participation in this trial.","ALL","18 Years",{"count":55,"type":56},18,"ESTIMATED","INTERVENTIONAL",[59],"PHASE1","A multicenter, open, single arm dose escalation and dose expansion phase I study to evaluate the safety, tolerability, and efficacy of SCG142 TCR-T cells in Subjects with advanced HPV associated carcinomas.",[62,63,64,65,66,67,68,69],"Human Papillomavirus Associated Carcinomas","Cervical Cancer","Head and Neck Cancers","Anal Cancer","Vulva Cancer","Vaginal Cancer","Penile Cancer","HPV-Related Malignancy","2024-08-06",{"date":72,"type":73},"2024-08-09","ACTUAL",{"date":75,"type":73},"2023-08-02",{"date":77,"type":56},"2026-12-31",{"name":5,"class":6},1]